Publications by authors named "Kin Man Loke"
Article Synopsis
- Mesenchymal stem cells (MSCs) are being researched as potential carriers to deliver cancer treatments due to their ability to target tumors, with previous studies showing promising anti-tumor effects in mice and other animals using specific genetic engineering.
- This study aimed to enhance cancer treatment by co-administering engineered MSCs that express two therapeutic agents (CDUPRT and IFNb) alongside a prodrug system, while assessing their effectiveness through various experiments.
- Results indicated that the engineered MSCs maintained their migratory abilities after genetic modifications, and showed improved anti-cancer efficacy when CDUPRT and IFNb were co-expressed compared to when only CDUPRT was used.
Background: Mesenchymal stem cells (MSCs) driven gene directed enzyme prodrug therapy is a promising approach to deliver therapeutic agents to target heterogenous solid tumours. To democratize such a therapy, cryopreservation along with cold chain transportation is an essential part of the logistical process and supply chain. Previously, we have successfully engineered MSCs by a non-viral DNA transfection approach for prolonged and exceptionally high expression of the fused transgene cytosine deaminase, uracil phosphoribosyl transferase and green fluorescent protein (CD::UPRT::GFP).
View Article and Find Full Text PDFM2-type TAMs are increasingly implicated as a crucial factor promoting metastasis. Numerous cell types dictate monocyte differentiation into M2 TAMs via a complex network of cytokine-based communication. Elucidating critical pathways in this network can provide new targets for inhibiting metastasis.
View Article and Find Full Text PDF